Filtered By:
Source: Clinical Cardiology
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 111 results found since Jan 2013.
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial
We examined these associations for medically managed ACS patients randomized to dual antiplatelet therapy (DAPT) using patient data from the TRILOGY ACS trial. DAPT included aspirin plus clopidogrel 75 mg/d or prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years). Patients receiving oral anticoagulants were excluded. Cox proportional hazards regression modeling was used to characterize associations between patients with AF (AF+) vs those without (AF−) and risk of ischemic and bleeding events, and to explore effects of randomized treatment on outcomes. Among 9101 patients with baseline AF status, 710...
Source: Clinical Cardiology - June 30, 2016 Category: Cardiology Authors: Larry R. Jackson, Jonathan P. Piccini, Derek D. Cyr, Matthew T. Roe, Megan L. Neely, Felipe Martinez, Thomas F. L üscher, Renato D. Lopes, Kenneth J. Winters, Harvey D. White, Paul W. Armstrong, Keith A.A. Fox, Dorairaj Prabhakaran, Deepak L. Bhatt, E. M Tags: Clinical Trial Updates Source Type: research
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy
ConclusionsWithin this XANTUS cohort, switching from a VKA to rivaroxaban yielded statistically and clinically significant improvements in ACT burden and benefit scores.
Source: Clinical Cardiology - June 29, 2016 Category: Cardiology Authors: Craig I. Coleman, Sylvia Haas, Alexander G.G. Turpie, Silvia Kuhls, Susanne Hess, Thomas Evers, Pierre Amarenco, Paulus Kirchhof, A. John Camm, Tags: Clinical Investigations Source Type: research
Prasugrel Use in Real Life: A Report From the Outpatient Setting in France
The objective of this study was to provide descriptive statistics on patterns of prasugrel usage in the outpatient setting in France. This retrospective study was conducted to describe treatment patterns for prasugrel in the outpatient setting in France using the Intercontinental Marketing Services (IMS) Disease Analyzer database, which collates electronic medical records updated by a nationally representative database of 1200 French general practitioners (GPs). Anonymous data were collected prospectively at each follow‐up visit. The study population consisted of patients with ≥1 prescription for prasugrel in the outpa...
Source: Clinical Cardiology - April 30, 2016 Category: Cardiology Authors: Pierre Sabouret, Magali Taiel‐Sartral, Florence Chartier, Sabine Akiki, Thomas Cuisset Tags: Quality and Outcomes Source Type: research
Postoperative Strokes and Intracranial Bleeds in Patients With Atrial Fibrillation: The FibStroke Study
ConclusionsPerioperative interruption of OAC is common in patients who suffer a postoperative stroke, even in patients with low‐bleeding‐risk procedures. Postoperative intracranial bleeding is frequently preceded by perioperative heparin bridging.
Source: Clinical Cardiology - April 30, 2016 Category: Cardiology Authors: Antti Palomäki, Tuomas Kiviniemi, Juha E.K. Hartikainen, Pirjo Mustonen, Antti Ylitalo, Ilpo Nuotio, Päivi Hartikainen, Jussi Jaakkola, Riho Luite, K.E. Juhani Airaksinen Tags: Clinical Investigations Source Type: research
Association Between Very Low Levels of High‐Density Lipoprotein Cholesterol and Long‐term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial
ConclusionsMedically managed ACS patients with very low baseline HDL‐C levels have higher risk of long‐term cardiovascular and all‐cause death but similar risks for nonfatal ischemic outcomes vs patients with higher baseline HDL‐C.
Source: Clinical Cardiology - March 31, 2016 Category: Cardiology Authors: Emil Hagström, Matthew T. Roe, Gail Hafley, Megan L. Neely, Mandeep S. Sidhu, Kenneth J. Winters, Dorairaj Prabhakaran, Harvey D. White, Paul W. Armstrong, Keith A.A. Fox, E. Magnus Ohman, William E. Boden, Tags: Clinical Investigations Source Type: research
Stroke and Systemic Embolism After Successful Ablation of Typical Atrial Flutter
ConclusionsPatients with AFL who undergo successful ablation are by no means free from embolic complications during long‐term follow‐up, mainly due to a high rate of AF development. Given the difficulties in detecting AF and the uncertainty about the temporal relation of AF and stroke, oral anticoagulation may need to be continued in those patients with underlying stroke risk factors.
Source: Clinical Cardiology - March 29, 2016 Category: Cardiology Authors: Víctor Expósito, Felipe Rodríguez‐Entem, Susana González‐Enríquez, Gabriela Veiga, Iván Olavarri, Juan J. Olalla Tags: Clinical Investigations Source Type: research
Clinical Outcome of First‐ vs Second‐Generation DES According to DAPT Duration: Results of ARCTIC‐Generation
ABSTRACT
There is an apparent benefit with extension of dual antiplatelet therapy (DAPT) beyond 1 year after implantation of drug‐eluting stents (DES). Assessment by a Double Randomization of a Conventional Antiplatelet Strategy vs a Monitoring‐Guided Strategy for Drug‐Eluting Stent Implantation, and of Treatment Interruption vs Continuation One Year After Stenting (ARCTIC)‐Generation assessed whether there is a difference of outcome between first‐ vs second‐generation DES and if there is an interaction with DAPT duration in the ARCTIC‐Interruption study. ARCTIC‐Interruption randomly allocated 1259 patients...
Source: Clinical Cardiology - February 16, 2016 Category: Cardiology Authors: Jean‐Philippe Collet, Johanne Silvain, Mathieu Kerneis, Thomas Cuisset, Nicolas Meneveau, Ziad Boueri, Olivier Barthélémy, Grégoire Rangé, Guillaume Cayla, Eric Van Belle, Simon Elhadad, Didier Carrié, Christophe Caussin, Hélène Rousseau, Pierre Tags: Clinical Trial Updates Source Type: research
Where There's Smoke, There's Fire? Significance of Atrial Fibrillation in Young Patients
ConclusionsAtrial fibrillation occurs in young patients with and without structural heart disease. Young AF patients without comorbidities rarely develop CVD during the first years after diagnosis. Yet, an SVT is found in a high proportion of young AF patients; AF may be first manifestation of SVT. Therefore, young patients should undergo further evaluation for SVT
Source: Clinical Cardiology - February 5, 2016 Category: Cardiology Authors: Alexander Wutzler, Sophie von Ulmenstein, Philipp Attanasio, Martin Huemer, Abdul Shokor Parwani, Katharina Völk, Florian Blaschke, Leif‐Hendrik Boldt, Wilhelm Haverkamp Tags: Clinical Investigations Source Type: research
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications
ConclusionsThe risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel. However, caution with use of bridging anticoagulation should be taken when using ticagrelor.
Source: Clinical Cardiology - January 8, 2016 Category: Cardiology Authors: Angel Fu, Kuljit Singh, Joseph Abunassar, Nikita Malhotra, Michel Le May, Marino Labinaz, Christopher Glover, Jean‐Francois Marquis, Michael Froeschl, Alexander Dick, Benjamin Hibbert, Aun‐Yeong Chong, Derek Y. F. So, Tags: Clinical Investigations Source Type: research
Impact of Awareness and Patterns of Nonhospitalized Atrial Fibrillation on the Risk of Mortality: The Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study
ConclusionsAsymptomatic, nonhospitalized AF is associated with an increased risk of mortality in the general population. Mortality is higher in those with ECG‐confirmed cases and among those who are unaware of their diagnosis.
Source: Clinical Cardiology - January 1, 2016 Category: Cardiology Authors: Wesley T. O'Neal, Jimmy T. Efird, Suzanne E. Judd, Leslie A. McClure, Virginia J. Howard, George Howard, Elsayed Z. Soliman Tags: Clinical Investigations Source Type: research
The HAS‐BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta‐analysis
ABSTRACT
Our objective was to compare the diagnostic accuracy between the HAS‐BLED score and any of HEMORR2HAGES, ATRIA, CHADS2, or CHA2DS2‐VASc scores in anticoagulated patients with atrial fibrillation. We systematically searched the Cochrane Library, MEDLINE, PubMed, and Embase databases for relevant studies. Data were extracted and analyzed according to predefined clinical endpoints. Eleven studies were identified. Discrimination analysis demonstrates that HAS‐BLED has no significant C‐statistic differences for bleeding risk prediction compared with ATRIA or HEMORR2HAGES, but it has significant differences comp...
Source: Clinical Cardiology - September 29, 2015 Category: Cardiology Authors: Wengen Zhu, Wenfeng He, Linjuan Guo, Xixing Wang, Kui Hong Tags: Review Source Type: research
Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device
ConclusionsOur pilot study suggests that NOAC therapy within the first 45 days after interventional LAA closure is safe and effective.
Source: Clinical Cardiology - September 1, 2015 Category: Cardiology Authors: Leif I. Bösche, Faegheh Afshari, Dominik Schöne, Aydan Ewers, Andreas Mügge, Michael Gotzmann Tags: Clinical Investigations Source Type: research
Effect of Low‐Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta‐Analyses, and Meta‐Regression Analyses of Randomized Trials
ABSTRACT
This analysis investigated the extent of different outcome reductions from low‐density lipoprotein cholesterol (LDL‐C) lowering following ezetimibe/simvastatin treatment and the proportionality of outcome to LDL‐C reductions. The authors searched PubMed between 1997 and mid‐June 2015 (any language) and the Cochrane Library to identify all randomized controlled trials comparing ezetimibe/simvastatin with placebo or less intensive LDL‐C lowering. Risk ratios (RR) and 95% confidence intervals (CIs), standardized to 20 mg/dL LDL‐C reduction, were calculated for 5 primary outcomes (fatal and nonfatal) and...
Source: Clinical Cardiology - August 18, 2015 Category: Cardiology Authors: Costas Thomopoulos, George Skalis, Helena Michalopoulou, Costas Tsioufis, Thomas Makris Tags: Review Source Type: research
Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review
ABSTRACT
Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to an increased risk of embolic stroke. After nearly 60 years, warfarin is no longer the only effective therapeutic option for patients with AF. Large randomized trials have consistently shown that non–vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban significantly reduce from the risk of intracranial hemorrhage (ICH) compared with warfarin. We provide a focused review regarding the NOACs and ICH in AF patients by summarizing findings of these large clinical trials, mechanisms of ...
Source: Clinical Cardiology - July 14, 2015 Category: Cardiology Authors: Boris Arbit, Jonathan C. Hsu Tags: Review Source Type: research
Benefit of Anticoagulation Therapy in Hyperthyroidism‐Related Atrial Fibrillation
ConclusionsPatients with hyperthyroidism‐related AF are at high risk of stroke (3.9% per year). Warfarin confers stroke prevention in patients with CHA2DS2‐VASc ≥1 and non–self‐limiting AF. Overall stroke risk was lower in hyperthyroid non–self‐limiting AF patients compared with nonhyperthyroid counterparts.
Source: Clinical Cardiology - July 1, 2015 Category: Cardiology Authors: Pak‐Hei Chan, Jojo Hai, Chun‐Yip Yeung, Gregory Y.H. Lip, Karen Siu‐Ling Lam, Hung‐Fat Tse, Chung‐Wah Siu Tags: Clinical Investigations Source Type: research
